Last reviewed · How we verify
Acute migraine treatment
Approved treatments
- BHV-3500 (zavegepant) · Pfizer Inc.
Zavegepant is a CGRP receptor antagonist that blocks neuropeptide signaling to reduce migraine pain and associated symptoms. - BHV-3500 (zavegepant) · Pfizer Inc.
Zavegepant is a CGRP receptor antagonist that blocks neuropeptide signaling to reduce migraine pain and associated symptoms.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Acute migraine treatment patent landscape — cliff calendar, originator estates, attackable patents
- Acute migraine treatment treatment landscape brief
- Acute migraine treatment treatment updates RSS
Frequently asked questions about Acute migraine treatment
What drugs treat Acute migraine treatment?
Tracked treatments include BHV-3500 (zavegepant).
What is the treatment for Acute migraine treatment?
Standard treatment for Acute migraine treatment includes BHV-3500 (zavegepant). See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Acute migraine treatment patent cliff · Acute migraine treatment CI report
- Treatment: BHV-3500 (zavegepant) · Pfizer Inc.
- Treatment: BHV-3500 (zavegepant) · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing